CSE Bulletin: Fundamental Change - FogChain Corp./Avisa Diagnostics Inc.

Avisa Diagnostics Inc., the issuer resulting from a Fundamental Change of FogChain Corp. (FOG.X), has been approved for listing.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

The Issuer offers an innovative approach to treating lung infections with rapid diagnostics to guide better clinical outcomes.

_________________________________

Avisa Diagnostics Inc., l'émetteur résultant d'un changement fondamental de FogChain Corp.(FOG.X), a été approuvé pour inscription.

Les documents de cotation et de divulgation seront disponibles sur www.thecse.com à la date de négociation.

L'émetteur propose une approche innovante pour traiter les infections pulmonaires avec des diagnostics rapides pour guider de meilleurs résultats cliniques.

Issuer/Émetteur: Avisa Diagnostics Inc.
Security Type/Titre: Common Shares/Actions ordinaires
Symbol(s)/Symbole(s): AVBT
Number of securities issued and outstanding/ Titres émis et en circulation: 41 219 310
Number of Securities reserved for issuance/ Titres réservés pour émission: 25 594 334
CSE Sector/Catégorie: Life Sciences/Sciences biologiques
CUSIP : 05380J 10 7
ISIN : CA 05380J 10 7 5
Old/Vieux CUSIP& ISIN: 34417N105/CA34417N1050
Boardlot/Quotité: 500
Consolidation: 1 New for 15 Old /1 nouveau pour 15 ancien
Trading Currency/Monnaie de négociation: CDN$/$CDN
Trading Date/Date de negociation: le 18 mai/May 2021
Other Exchanges/Autres marches: N/A
Fiscal Year end /Clôture de l'exercice financier: le 31 décembre/December
Transfer Agent/Agent des transferts: TSX Trust Company

 

The Exchange is accepting Market Maker applications for AVBT. Please email: Trading@theCSE.com

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com

Pour toute question, pour obtenir de l'information supplémentaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel à l'adresse: Listings@thecse.com

News Provided by Newsfile via QuoteMedia

The Conversation (0)

Jamieson Wellness Inc. Reports Strong Fourth Quarter and Full Year 2023 Results

Profitable revenue growth of 23.5% in 2023 demonstrates successful execution of global strategy;
Canadian consumer consumption reaches record levels in Q4

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today reported financial results for its fourth quarter and full year results for the period ended December 31, 2023. All amounts are expressed in Canadian dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS and other financial measures. See "Non-IFRS and Other Financial Measures" below.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Jamieson Wellness Inc. Announces Date of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) announced today that the Company will release its fourth quarter and full year 2023 financial results after the market close on Wednesday, March 13, 2024. The Company will host a conference call for investors at 5:00 p.m. Eastern Time to discuss the fourth quarter and full year 2023 results.

The call can be accessed live over the telephone by dialing 1-888-886-7786 from Canada and the U.S. or 1-416-764-8658 from international locations. A replay will be available shortly after the call and can be accessed by dialing 1-844-512-2921 from Canada and the U.S. or 1-412-317-6671 from international locations. The passcode for the replay is 82012546 and it will be available until Thursday, March 27, 2024.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Jamieson Wellness Inc. Declares Fourth Quarter 2023 Dividend

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) announced today that the board of directors of the Company has declared a cash dividend for the fourth quarter of 2023 of $0.19 per common share, or approximately $8.0 million in the aggregate. The dividend will be paid on March 15, 2024 to all common shareholders of record at the close of business on March 1, 2024. The Company has designated this dividend as an "eligible dividend" for the purposes of the Income Tax Act (Canada).

About Jamieson Wellness Inc.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx for Recurrent Pericarditis

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx for Recurrent Pericarditis

Topline Results Expected in Q2 2024

This is a Designated News Release.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Principal Technologies (TSXV:PTEC)

Principal Technologies


Keep reading...Show less
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II Study

This is a Designated News Release.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×